Health Catalyst, Inc. (NASDAQ:HCAT) Receives $9.45 Consensus Price Target from Brokerages

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $9.27.

Several analysts recently weighed in on HCAT shares. Piper Sandler lowered their price objective on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 11th. Stifel Nicolaus lowered their target price on Health Catalyst from $10.00 to $5.00 and set a “hold” rating for the company in a report on Thursday, February 27th. Citigroup lowered their target price on Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a report on Friday, January 10th. KeyCorp raised Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price for the company in a report on Wednesday, January 8th. Finally, Royal Bank of Canada lowered their target price on Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating for the company in a report on Thursday, February 27th.

Insiders Place Their Bets

In other Health Catalyst news, insider Linda Llewelyn sold 6,441 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $5.43, for a total value of $34,974.63. Following the completion of the sale, the insider now directly owns 85,819 shares in the company, valued at $465,997.17. This represents a 6.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Duncan Gallagher sold 4,500 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $6.93, for a total value of $31,185.00. Following the completion of the sale, the director now owns 69,938 shares of the company’s stock, valued at $484,670.34. This trade represents a 6.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 41,243 shares of company stock worth $273,620 over the last ninety days. Company insiders own 2.50% of the company’s stock.

Institutional Trading of Health Catalyst

Several large investors have recently added to or reduced their stakes in the company. Probity Advisors Inc. raised its stake in Health Catalyst by 33.2% during the 4th quarter. Probity Advisors Inc. now owns 30,692 shares of the company’s stock valued at $217,000 after purchasing an additional 7,647 shares during the period. Mackenzie Financial Corp acquired a new stake in Health Catalyst during the 4th quarter valued at $248,000. PharVision Advisers LLC acquired a new stake in Health Catalyst during the 4th quarter valued at $185,000. Two Sigma Advisers LP raised its stake in Health Catalyst by 72.7% during the 4th quarter. Two Sigma Advisers LP now owns 29,700 shares of the company’s stock valued at $210,000 after purchasing an additional 12,500 shares during the period. Finally, Two Sigma Investments LP acquired a new stake in Health Catalyst during the 4th quarter valued at $496,000. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Stock Down 3.2 %

Shares of Health Catalyst stock opened at $4.29 on Wednesday. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The firm has a market cap of $301.21 million, a P/E ratio of -3.18 and a beta of 1.41. Health Catalyst has a fifty-two week low of $3.76 and a fifty-two week high of $9.24. The business has a 50-day moving average price of $5.73 and a 200 day moving average price of $7.16.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.